Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Plus Bevacizumab in Pretreated Advanced NSCLC
NCT00741195Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Apr 2008
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Started Apr 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00741195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741195.